The detection of DDIT3 rearrangements can be useful in diagnosing myxoid liposarcoma – including uncommon histologic variants – and in distinguishing this sarcoma from other mesenchymal tumors that may be considered in the differential diagnosis.
In an effort to ensure the safety of our faculty and staff, while maintaining service excellence for our clients and mutual patients, Michigan Medicine Laboratories (MLabs) has updated our tissue submission requirements.
We have changed our location for COVID testing to an inside drive through to Huron Valley Ambulance Center (HVA).
MLabs is now offering PDL-1 testing for Metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
Many patients living with metastatic breast cancer (mBS) now have a new treatment option.
In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...
MLabs NGS Panels Detects NTRK Fusion Genes in Select Solid Tumor Patients for FDA-approved Vitrakvi® (larotrectinib) Therapy
MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...